Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine

Valneva’s plans to establish its COVID-19 vaccine as a booster to Pfizer and BioNTech’s Comirnaty have taken a blow, with a clinical trial of the shot eliciting “only a marginally increased neutralizing antibody response.”